Integral DiagnosticsITGDF 72 3-Year ROIIC % is 0.03 as of Jun. 2025, which is 99% below its 10-year median of 4.01. GuruFocus rates ITGDF with a GF Score™ of 72/100 and a GF Value™ of $1.17 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 50.49% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Integral Diagnostics's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 0.03%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Integral Diagnostics's 3-Year ROIIC % or its related term are showing as below:
ITGDF's 3-Year ROIIC % is ranked worse than 50.49% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.125
vs ITGDF: 0.03
Integral Diagnostics (OTCPK:ITGDF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Integral Diagnostics 3-Year ROIIC % Related Terms
Integral Diagnostics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ITGDF vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Integral Diagnostics (ITGDF) has a 3-Year ROIIC % of 0.03 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Integral Diagnostics and its competitors. This is 99% below median its historical median of 4.01. According to the industry distribution chart, Integral Diagnostics ranks #103 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 50.5%.
Is Integral Diagnostics' 3-Year ROIIC % too high?
Integral Diagnostics' current 3-Year ROIIC % of 0.03 is 99% below median its 10-year median of 4.01. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.13. Integral Diagnostics' value of 0.03 is 76% below this industry median. Based on the distribution chart, Integral Diagnostics ranks #103 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #103 out of 204 companies for 3-Year ROIIC %. This places Integral Diagnostics in the lower half of its industry. The industry median 3-Year ROIIC % is 0.13. Integral Diagnostics' value of 0.03 is 76% below this benchmark. While the company's 10-year median is 4.01 vs. the industry median of 0.13, Integral Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.13, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integral Diagnostics's current 3-Year ROIIC % of 0.03 is 76% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Integral Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integral Diagnostics's current 3-Year ROIIC % is 0.03, which is 99% below median its own 10-year median of 4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ITGDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $2.61 — trading 123.3% above its estimated fair value. The current 3-Year ROIIC % is 0.03, which is 99% below median its 10-year median of 4.01 and 76% below the Medical Diagnostics & Research industry median of 0.13. Integral Diagnostics' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Integral Diagnostics (ITGDF), the current 3-Year ROIIC % is 0.03 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ITGDF) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be overvalued.
The current stock price of $2.61 is trading 123.3% above its estimated GF Value™ of $1.17.
GuruFocus considers Integral Diagnostics to be Significantly Overvalued.
Key valuation signals for ITGDF:
3-Year ROIIC %: 0.03 (99% below median its 10-year median of 4.01)
GF Value™: $1.17 vs. price of $2.61 (123.3% above fair value)
Industry Position: 76% below the Medical Diagnostics & Research median (#103 of 204)
No single metric tells the full story. See the ITGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
72GF Score
Get the complete analysis for ITGDF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ITGDF has been successfully added to your 
